Appendix • Noninvasive Composite Scores

Experimental/Emerging Composite Scores

Multi-modality algorithms pairing elastography imaging with blood biomarkers and clinical factors to narrow indeterminate zones.

What This Means for Patients

When a blood test says one thing and an imaging scan lands in a borderline gray zone, combining both into a single composite score shrinks the uncertainty. FAST, Agile 3+, and Agile 4 combine your FibroScan numbers with routine labs like AST, ALT, platelets, and diabetes status right inside clinic apps, while MEFIB and MAST pair MRI scans with blood work to pinpoint 'at-risk' MASH (active inflammation plus stage F2 or higher scarring) without needing a biopsy.

Emerging Composite Tools for Noninvasive Fibrosis Assessment in MASLD1-3

Subtest Parameters Involved Applications Cutoff Sensitivity, %a Specificity, %b
MEFIB1,4 MRE + FIB-4 score Identifies MASHc and ≥F2 Rule in:
MRE: ≥3.3 kPa
plus
FIB-4: ≥1.6
NR NR
MAST2,4 MRI-PDFF, MRE, and AST Identifies MASHc and ≥F2 Rule out: ≤0.165 72.2 89.3
Rule in: ≥0.242 90.3 75.0
FAST5,d LSM by VCTE™, CAP™ + AST Identifies MASHc and ≥F2 Rule out: ≤0.35 89.0 64.0
Rule in: ≥0.67 49.0 92.0
Agile 3+6,d LSM by VCTE™ + AST + ALT + platelets + diabetes status + sex + age Identifies ≥F3 in patients with MASLD Rule out: <0.451 82.0 75.0
Rule in: ≥0.679 61.0 87.0
Agile 46,d LSM by VCTE™ + AST + ALT + platelets + diabetes status + sex Identifies F4 in patients with MASLD Rule out: <0.251 87.0 86.0
Rule in: ≥0.565 55.0 97.0